As filed with the Securities and Exchange Commission on October 16, 2019
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
BIOMARIN PHARMACEUTICAL INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
68-0397820
|
(State or other jurisdiction of
Incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
770 Lindaro Street
San
Rafael, CA 94901
(Address of principal executive offices) (Zip code)
BioMarin Pharmaceutical Inc. 2017 Equity Incentive Plan, as Amended April 12, 2019
BioMarin Pharmaceutical Inc. Amended and Restated 2006 Employee Stock Purchase Plan, as Amended and
Restated April 12, 2019
(Full title of the plan)
G. Eric Davis
Executive Vice President, General Counsel
BioMarin Pharmaceutical Inc.
770 Lindaro Street
San
Rafael, California 94901
(415) 506-6700
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
Jodie
M. Bourdet
Siana E. Lowrey
Cooley LLP
101
California Street
5th Floor
San Francisco, CA 94111-5800
(415) 693-2000
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated
filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☒
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☐
|
|
Smaller reporting company
|
|
☐
|
|
|
|
|
Emerging growth company
|
|
☐
|
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐